Menu
ncarol.com
  • Home
  • Business
  • Health
  • Real Estate
  • Arts
  • Non-profit
  • Education
  • Technology
  • Books
ncarol.com

First Choice Neurology Pioneering Neurologists Administer the New FDA-Approved Drug Kisunla
ncarol.com/10266657

Trending...
  • New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
  • Why Regular Visits to a Dentist in Kernersville Protect More Than Just Your Smile
  • SacraPod Suites Unveils AI-Powered 'Work + Rest' Smart Hospitality Model for Retrofitting Underused Motels Across the U.S
Kisunla FDA Approved for Alzheimers
JUPITER, Fla. - ncarol.com -- First Choice Neurology, the largest neurology group in the United States, is set to make medical history next week as Dr. Jennifer Buczyner and Dr. Jeff Gelblum are among the first physicians in the country to administer the newly FDA-approved drug Kisunla to patients. This groundbreaking development marks a significant milestone in neurological care, offering new hope to patients battling a range of neurological conditions.

Kisunla, by Eli Lilly represents a promising advancement in neurology, specifically targeting Alzheimer's disease and dementia. Kisunla is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.

Dr. Jeff Gelblum, Neurologist in Aventura, Florida, has significant experience using anti-amyloid infusion therapy for his patients with mild cognitive impairment and mild Alzheimer's disease. He has many patients taking Leqembi with which was FDA approved in July 2023.

He is also looking forward to using Kisunla in his patients for the same conditions and differentiates the two products, accordingly: "The two drugs target the same endpoint, reduction of brain amyloid plaque which is a marker of Alzheimer's disease. Leqembi is given twice a month for a full 18 months. Kisunla is once a month and may be able to be stopped as soon as six months, based upon clearance of amyloid plaque on a follow up brain PET scan. Leqembi has a lower incidence of side effects of brain swelling and bleeding."

More on ncarol.com
  • Hilton Charlotte Uptown Hosts First-Ever Premium Tailgate Experience
  • Assent Expands Executive Team to Accelerate Global Growth & Innovation
  • The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
  • Vinnetwork Unveils Decentralized AI Platform with Vinnetwork(VIN) Token to Challenge Tech Giants' Data Monopoly
  • Centennial Flyers to Become Colorado's First Launch Customer for All-Electric B23 Energic Aircraft

Gelblum notes, "that a patient who is unable to go for twice monthly infusions and eager to possibly conclude treatment in as soon as six months, who can also assume the greater safety risk, would be a good candidate for the new treatment."

Dr. Jennifer Buczyner, Neurologist in Jupiter, Florida said, "The approval of Kisunla offers another opportunity for patients with mild cognitive impairment or mild dementia and brings those with mild cognitive impairment to early medical attention. In studies, Kisunla slowed cognitive and functional decline by up to 35 percent compared to placebo at 18 months and reduced patients' risk of progressing to the next clinical stage of disease by up to 39 percent.  We at First Choice Neurology are very excited to offer anti-amyloid therapies to our South Florida communities."

The introduction of Kisunla underscores First Choice Neurology's commitment to pioneering treatments that transform the landscape of neurological care. As the first physicians in the United States to administer Kisunla, Dr. Gelblum and Dr. Buczyner exemplify the group's leadership in bringing cutting-edge therapies to patients.

More on ncarol.com
  • Pyro Marketing Opens New Digital Marketing Company in Saint Petersburg to Power Growth for Fitness and Ecommerce Brands
  • Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments
  • $14M Expansion Deal with Famed David Lloyd Highlights Rebrand of Sports, Entertainment and Gaming Innovation by AI Driven, Online Fan Engagement Co
  • Marvelous Mouse Talk Named One of the Top 100 Disney Podcasts by MillionPodcasts
  • Heartfelt Dreams Foundation Launches Campaign to Build CHD Hospital

About First Choice Neurology
First Choice Neurology is the largest neurology group in the United States with over 60 Care Centers in multiple Florida counties and services at more than 45 major hospitals. The group provides comprehensive neurological care for patients with a wide range of conditions including Alzheimer's disease, dementia, epilepsy, migraines, multiple sclerosis, Parkinson's disease, sleep disorders, strokes, traumatic brain injuries, and more. With a commitment to innovation and patient-centered care, First Choice Neurology continues to lead advancements in neurological treatments nationwide.

For more information about Kisunla and First Choice Neurology, visit fcneurology.com

Contact
First Choice Neurology
***@fcneurology.net


Source: First Choice Neurology
Filed Under: Health

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Robin Launches Legal Intelligence Platform to solve intelligence gap in Fortune 500 legal teams
  • Melissa B. Releases Digitally Independent: Empowering Music Artists with AI and Brand Strategy
  • Consumer Accountability Alliance Issues Formal Notice Alleging Proximate Liability for Medical Harm
  • Utah Metal Fabricator Titan Forge Builds Momentum with Custom Steel Projects and Spiral Staircases
  • Jason Koch: Pioneering the Future of Real Estate Development in New Jersey
  • Magical Creatures Hit the Hallways in Captain Cougar Goes to School
  • Bach and Beyond: Cellists Return to the Beach for 2nd Annual Bethany Beach Cellofest
  • Hinuera Properties and The Sage Plant Announce Modern Townhome Project in the Piedmont Triad
  • The Sage Plant Drives PropTech in the Piedmont Triad
  • NR7 Miner launches zero-cost USDT cloud mining service: daily stable income + referral rewards for double profit
  • Deaths Spur Closures, but Troubled Teen Camps Must Be Banned, CCHR Warns
  • Palmer Lake Wine Festival To Build Bridges in Small Mountain Community, Highlight Local Businesses
  • SacraPod Suites Unveils AI-Powered 'Work + Rest' Smart Hospitality Model for Retrofitting Underused Motels Across the U.S
  • From Real Estate to Reel Power: H.L Woods Carves His Legacy as a Cutting-Edge Visionary Filmmaker
  • Veterans for America First's Vet Force community outreach is expanding said David Draper VFAF
  • New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
  • Why Regular Visits to a Dentist in Kernersville Protect More Than Just Your Smile
  • O2 Fitness Opens New Signature Location in Pittsboro, NC
  • Cynthia Pinot Among Artists Selected for Renowned London Art Biennale 2025
  • Real Estate Experts Highlight Jersey Shore as a Smart Buy in 2025
_catLbl0 _catLbl1

Popular on ncarol.com

  • Experience Trembling Firsthand with the New AgeMan® Tremor Simulator - 124
  • csky.ai & DuoKey Launch Secure AI Transcription Solution for Microsoft 365
  • Mauro Schnaidman named as Managing Director in Miami, Florida
  • Continued Streak of Recognitions with Multiple Chambers and Partners Rankings
  • Innovative EDM Music Project, "Terms of War," Depicts an A.I. Takeover of Earth
  • LIB Continuous Innovation: Custom Rain Test Chambers & IP Labs
  • Local Clinic Fills the Gaps Politicians Don't Want to Talk About
  • Jeopardy!'s Ken Jennings Headlines National Mensa Event
  • OPRAH.COM Featured Award-Winning Novel AS FAR AS YOU GO BEFORE YOU HAVE TO COME BACK now Available as Audiobook
  • Mensa Foundation Prize Awarded to Neuroscientist-Pianist

Similar on ncarol.com

  • Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
  • Colbert Packaging Announces WBENC Recognition
  • Pyro Marketing Opens New Digital Marketing Company in Saint Petersburg to Power Growth for Fitness and Ecommerce Brands
  • Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments
  • Heartfelt Dreams Foundation Launches Campaign to Build CHD Hospital
  • Deaths Spur Closures, but Troubled Teen Camps Must Be Banned, CCHR Warns
  • Why Regular Visits to a Dentist in Kernersville Protect More Than Just Your Smile
  • West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
  • Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
  • New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
Copyright © 2025 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute